关于长期新冠的病因学理论。
Etiopathogenic theories about long COVID.
作者信息
Del Carpio-Orantes Luis
机构信息
Department of Internal Medicine, Virology, Research, Study Group for the Diagnosis and Treatment of COVID-19 in Veracruz, Veracruz 91900, Veracruz, Mexico.
出版信息
World J Virol. 2023 Jun 25;12(3):204-208. doi: 10.5501/wjv.v12.i3.204.
Abstract
The main etiopathogenic theories of long coronavirus disease (COVID) are listed and a conjunction of them is carried out with the objective of deciphering the pathophysiology of the entity, finally the main lines of treatment existing in real life are discussed (Paxlovid, use of antibiotics in dysbiosis, triple anticoagulant therapy, temelimab).
摘要
列出了长期新冠病毒病（COVID）的主要病因学理论，并将它们结合起来以解读该疾病实体的病理生理学，最后讨论了现实生活中现有的主要治疗方法（帕罗韦德、在菌群失调中使用抗生素、三联抗凝治疗、替麦利单抗）。
相似文献
1
Etiopathogenic theories about long COVID.关于长期新冠的病因学理论。
World J Virol. 2023 Jun 25;12(3):204-208. doi: 10.5501/wjv.v12.i3.204.
2
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.帕克洛维德降低高危患者的严重 2019 冠状病毒病和死亡率的有效性。
Clin Infect Dis. 2023 Feb 8;76(3):e342-e349. doi: 10.1093/cid/ciac443.
3
Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature.普克鲁胺治疗帕罗韦德治疗后 COVID-19 反弹：四例报告及文献复习。
J Clin Lab Anal. 2023 Apr;37(7):e24880. doi: 10.1002/jcla.24880. Epub 2023 Apr 23.
4
Postmarketing Reporting of Paxlovid-Related Dysgeusia: A Real-World Pharmacovigilance Study.帕克洛维德相关味觉障碍的上市后报告：一项真实世界的药物警戒研究。
Otolaryngol Head Neck Surg. 2023 Jul;169(1):55-61. doi: 10.1002/ohn.278. Epub 2023 Feb 5.
5
Paxlovid (nirmatrelvir/ritonavir) effectiveness against hospitalization and death in N3C: A target trial emulation study.帕罗韦德（奈玛特韦/利托那韦）对N3C患者住院和死亡的有效性：一项目标试验模拟研究
medRxiv. 2023 Jun 3:2023.05.26.23290602. doi: 10.1101/2023.05.26.23290602.
6
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.加利福尼亚州 2021 年 12 月至 2022 年 5 月辉瑞公司新冠口服药 Paxlovid 治疗后因 COVID-19 住院和急诊就诊情况。
MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):830-833. doi: 10.15585/mmwr.mm7125e2.
7
Paxlovid for Treating COVID-19 Patients: A Case-Control Study From Two Hospitals in the Eastern Province of Saudi Arabia.帕罗韦德治疗新冠肺炎患者：沙特阿拉伯东部省份两家医院的病例对照研究
Cureus. 2023 May 19;15(5):e39234. doi: 10.7759/cureus.39234. eCollection 2023 May.
8
The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2.在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变种疫情期间，帕罗韦德治疗在韩国长期护理机构中的有效性。
Osong Public Health Res Perspect. 2022 Dec;13(6):443-447. doi: 10.24171/j.phrp.2022.0262. Epub 2022 Dec 23.
9
Real-world effectiveness of granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study.基于颗粒剂的治疗对感染严重急性呼吸综合征冠状病毒2奥密克戎变种BA.2并伴有高危因素患者的真实世界疗效：一项队列研究。
Front Pharmacol. 2022 Aug 16;13:978979. doi: 10.3389/fphar.2022.978979. eCollection 2022.
10
The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6-14 years: a cohort study.帕罗韦德治疗6至14岁新冠病毒感染儿童的可行性、安全性和有效性：一项队列研究
Ann Transl Med. 2022 Jun;10(11):619. doi: 10.21037/atm-22-2791.
引用本文的文献
1
Neuropsychiatric manifestations in patients with long COVID in Mexico.墨西哥长期新冠患者的神经精神表现
Brain Circ. 2023 Sep 27;9(3):196-197. doi: 10.4103/bc.bc_13_23. eCollection 2023 Jul-Sep.
2
Longitudinal clinical phenotyping of post COVID condition in Mexican adults recovering from severe COVID-19: a prospective cohort study.墨西哥成年重症COVID-19康复者新冠后状况的纵向临床表型分析：一项前瞻性队列研究
Front Med (Lausanne). 2023 Aug 24;10:1236702. doi: 10.3389/fmed.2023.1236702. eCollection 2023.
本文引用的文献
1
Cardiovascular and haematological pathology in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A role for viruses.肌痛性脑脊髓炎/慢性疲劳综合征（ME/CFS）中的心血管和血液病理学：病毒的作用。
Blood Rev. 2023 Jul;60:101075. doi: 10.1016/j.blre.2023.101075. Epub 2023 Mar 20.
2
Dectin-1 signaling on colonic γδ T cells promotes psychosocial stress responses.肠 γδ T 细胞上的 Dectin-1 信号转导促进心理社会应激反应。
Nat Immunol. 2023 Apr;24(4):625-636. doi: 10.1038/s41590-023-01447-8. Epub 2023 Mar 20.
3
Long COVID: major findings, mechanisms and recommendations.长新冠：主要发现、机制和建议。
Nat Rev Microbiol. 2023 Mar;21(3):133-146. doi: 10.1038/s41579-022-00846-2. Epub 2023 Jan 13.
4
Long COVID and rheumatology: Clinical, diagnostic, and therapeutic implications.长新冠与风湿病学：临床、诊断和治疗意义。
Best Pract Res Clin Rheumatol. 2022 Dec;36(4):101794. doi: 10.1016/j.berh.2022.101794. Epub 2022 Nov 8.
5
Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae.持续循环的严重急性呼吸综合征冠状病毒 2 刺突蛋白与急性冠状病毒病 2019 后遗症有关。
Clin Infect Dis. 2023 Feb 8;76(3):e487-e490. doi: 10.1093/cid/ciac722.
6
Could tiny blood clots cause long COVID's puzzling symptoms?微小的血凝块会导致长期新冠的令人困惑的症状吗？
Nature. 2022 Aug;608(7924):662-664. doi: 10.1038/d41586-022-02286-7.
7
Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC).长新冠/COVID-19 后急性后遗症（PASC）患者的症状、合并症、纤维蛋白淀粉样微栓和血小板病理的流行情况。
Cardiovasc Diabetol. 2022 Aug 6;21(1):148. doi: 10.1186/s12933-022-01579-5.
8
Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing?替麦利单抗用于治疗多发性硬化症和新冠病毒：它会是一把双刃剑吗？
Mult Scler Relat Disord. 2022 Aug;64:103938. doi: 10.1016/j.msard.2022.103938. Epub 2022 Jun 6.
9
Amyloidogenesis of SARS-CoV-2 Spike Protein.新冠病毒刺突蛋白的淀粉样变性。
J Am Chem Soc. 2022 May 25;144(20):8945-8950. doi: 10.1021/jacs.2c03925. Epub 2022 May 17.
10
Autonomic dysfunction in long-COVID syndrome: a neurophysiological and neurosonology study.长新冠综合征中的自主神经功能障碍：一项神经生理学和神经超声学研究。
J Neurol. 2022 Sep;269(9):4611-4612. doi: 10.1007/s00415-022-11172-1. Epub 2022 May 10.
Zotero 插件